Shine and Telix ink Lu-177 supply deal

By AuntMinnie.com staff writers

February 10, 2022 -- Medical isotope company Shine Technologies and Telix Pharmaceuticals have signed an agreement covering the supply of lutetium-177 (Lu-177) to Telix for clinical development of potential new therapeutics to treat prostate and kidney cancer.

Under the clinical supply agreement, Shine will immediately commence supply of n.c.a. Lu-177 for use in clinical trials of Telix's therapeutic candidates TLX591 (Lu-177 rosopatamab for advanced prostate cancer) and TLX250 (Lu-177 girentuximab for kidney cancer), according to Shine.

Isotope production will take place at Shine's facility in Fitchburg, WI. Shine is currently expanding, with a new facility under construction in Janesville, WI, near its headquarters, and a facility in the design phase in Veendam, the Netherlands.


Copyright © 2022 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: